Danaher Corporation (DHR)
Health Care · Diversified industrial conglomerate / life sciences and diagnostics
A diversified conglomerate applying advanced technologies and quality manufacturing across life sciences, diagnostics, environmental & applied solutions, and industrial products.
What Danaher Corporation does
Danaher Corporation is a diversified conglomerate operating across multiple high-technology industries. The company manufactures and sells a broad range of products and services including life sciences tools, diagnostics platforms, water quality monitoring equipment, environmental solutions, and industrial products. Danaher serves customers in healthcare, pharmaceuticals, environmental testing, water treatment, and industrial sectors globally, competing on innovation, product quality, brand recognition, and operational efficiency. The company pursues growth through organic development, new product commercialization, and strategic acquisitions.
Themes: ["life sciences & research","diagnostics & healthcare","water quality & environmental monitoring","medical devices","pharmaceutical supply chain","healthcare cost containment","digital health capabilities","operational excellence","acquisitions & integration"]
Fundamentals
- Price$195.98 as of 2026-07-09 close
- Market cap$137.8B as of 2026-07-10
- 1-year return-4.9% as of 2026-07-09 close
- P/E37.35 as of 2026-07-10
- Net margin+14.9% as of 2026-07-10
- Gross margin+59.0% as of 2026-07-10
- ROE+7.1% as of 2026-07-10
- Debt / equity0.35 as of 2026-07-10
- Revenue growth (YoY)+4.0% as of 2026-07-10
- Revenue CAGR (3y)-2.7% SEC XBRL
- Beta0.78 as of 2026-07-10
Dividend: yield +0.8%; pays a dividend.
Key risks (from latest filing)
["Healthcare industry cost containment and government reimbursement pressure (including Clinical Laboratory Fee Schedule pricing controls) could reduce customer spending and product pricing","Rapid technological change and competitive pressure from disruptive technologies and low-cost competitors could obsolete existing product lines if R&D and innovation fail to keep pace","Product quality issues, safety alerts, or regulatory failures could harm brand reputation and market share, particularly in medical device and diagnostic segments where clinical outcomes and regulatory approvals are critical"]
Competitors & peers
- Thermo Fisher Scientific (FISH)
- Becton Dickinson (BDX)
- Avantor (AVTR)
- Hologic (HOLX)
- Perkinelmer (PKI)
- Bio-Rad Laboratories (BIO)
- Bruker (BRKR)
- Abbott Diagnostics (ABT)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.